Organization · Venture Capital
FCGP
Freepoint Capital Group (FCGP) is a healthcare-focused investment firm based in the United States, specializing in biotech, medtech, and healthcare innovation. The firm aims to accelerate the development of healthcare products and services that enhance clinical efficacy and accessibility.
Overview
What FCGP does
What FCGP is
Freepoint Capital Group (FCGP) is a healthcare-focused investment firm based in the United States, specializing in biotech, medtech, and healthcare innovation. The firm aims to accelerate the development of healthcare products and services that enhance clinical efficacy and accessibility.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- April 29, 2026
Official channels
Find FCGP elsewhere
Open the official website or a supported primary organization account.
Capability profile
FCGP as a funder
Investment thesis
Freepoint Capital Group focuses on healthcare innovation that enhances clinical efficacy, care quality, cost-effectiveness, and accessibility, particularly in life sciences, medical technology, and healthcare data.
Focus narrative
FCGP invests primarily in healthcare-focused companies, particularly those at the intersection of life sciences, medical technology, and healthcare data. The firm is particularly interested in later-stage investments, including Series A and growth-stage opportunities, that demonstrate validated products and clinical or commercial milestones.
Value beyond capital
FCGP adds value to its portfolio companies by leveraging its expertise in healthcare innovation, providing strategic guidance, and facilitating connections within the healthcare ecosystem to enhance product development and market entry.
Focus and fit
- Stages
- Series A · Growth Equity
- Regions
- United States
Availability
- Currently deploying
- Not published
Portfolio and track record
Portfolio context
Notable portfolio companies include Orasis Pharmaceuticals, an ophthalmic pharmaceutical company involved in the commercial launch of Qlosi for presbyopia; Bright Uro, a medtech company focused on urology; and Strand Therapeutics, which has received Series B funding.
Common questions
What to know about FCGP
Upseed classifies FCGP under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 29, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.